Catalog No.S3303 Synonyms: CYT

For research use only.

Cyperotundone (CYT) is an active constituent in Chuanxiong Rhizoma and Cyperi Rhizoma (CRCR) for treating migraine.

Cyperotundone Chemical Structure

CAS No. 3466-15-7

Purity & Quality Control

Related Other Products

Biological Activity

Description Cyperotundone (CYT) is an active constituent in Chuanxiong Rhizoma and Cyperi Rhizoma (CRCR) for treating migraine.

Protocol (from reference)

Chemical Information

Molecular Weight 218.33


Density 1.03 g/mL
CAS No. 3466-15-7
Storage 2 years -20°C liquid

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04927169 Recruiting Drug: Interleukin-7|Drug: PLACEBO COVID-19|Lymphocytopenia Revimmune|ReSolution Latin America S.A. March 1 2021 Phase 2
NCT04426201 Recruiting Drug: CYT107|Drug: Placebo COVID-19|Lymphocytopenia Revimmune|Memorial Sloan Kettering Cancer Center|Amarex Clinical Research|M.D. Anderson Cancer Center|Cancer Research Institute New York City December 20 2020 Phase 2
NCT04154826 Recruiting Drug: Recombinant human interleukin-7 Mycobacterium Infections Nontuberculous Revimmune|Washington University School of Medicine November 30 2020 Phase 2
NCT04442178 Recruiting Drug: CYT107|Drug: Placebo COVID-19|Lymphocytopenia Revimmune|Washington University School of Medicine|Amarex Clinical Research September 15 2020 Phase 2
NCT03941769 Recruiting Biological: Recombinant Interleukin-7 Acute Myeloid Leukemia|Chronic Myelogenous Leukemia BCR-ABL1 Positive|Cord Blood Transplant Recipient|Myelodysplastic Syndrome|Myeloproliferative Neoplasm M.D. Anderson Cancer Center|National Cancer Institute (NCI) September 29 2020 Phase 1

(data from, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Cyperotundone | Cyperotundone supplier | purchase Cyperotundone | Cyperotundone cost | Cyperotundone manufacturer | order Cyperotundone | Cyperotundone distributor